Sponsor
Erin Houchin
Representative · R-IN
Representative · R-IN
The bill preserves existing accreditation and prevents some sudden clinic restrictions, but at the cost of rolling back regulatory changes that could have expanded access and flexibility for medication treatment—potentially reducing treatment options and raising long-term public-health and economic costs.
People with opioid use disorder and the hospitals/health systems that serve them will remain subject to existing accreditation rules for opioid treatment programs, preserving program standards and oversight.
Hospitals, treatment providers, and state governments avoid immediate new clinic restrictions because certain rule provisions that could have limited operations are removed, reducing short-term operational disruption.
People with opioid use disorder may lose expanded access and flexibility in medication treatment that the nullified rule had authorized, potentially reducing treatment options and convenience.
Taxpayers and low-income communities could face higher long-term public-health and economic costs (more overdoses, hospitalizations, lost productivity) if rollback of access increases untreated opioid use disorder.
State governments and treatment providers may face regulatory uncertainty and added implementation costs as prior regulatory changes are reversed, disrupting care delivery and creating administrative burden.
Based on analysis of 2 sections of legislative text.
Nullifies HHS's final rule on medications for opioid use disorder but preserves the rule's changes to accreditation requirements for opioid treatment programs.
Official title: To provide that the final rule of the Department of Health and Human Services titled "Medications for the Treatment of Opioid Use Disorder", except for the portion of the final rule relating to accreditation of opioid treatment programs, shall have no force or effect.
Introduced September 30, 2025 by Erin Houchin · Last progress September 30, 2025
Nullifies the Department of Health and Human Services final rule titled "Medications for the Treatment of Opioid Use Disorder," removing that rule’s legal effect while preserving only the portions that change accreditation requirements for opioid treatment programs. The measure would reverse most regulatory changes in that HHS rule, restoring prior regulatory requirements for medications to treat opioid use disorder except for the specified accreditation modifications.